{"id":14938,"date":"2025-09-10T08:52:11","date_gmt":"2025-09-10T07:52:11","guid":{"rendered":"https:\/\/resemedicin.se\/reseradet\/?p=14938"},"modified":"2025-09-15T13:31:36","modified_gmt":"2025-09-15T12:31:36","slug":"2025-09-10-beyfortus-nirsevimab-till-nyfodda-i-sverige","status":"publish","type":"post","link":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-09-10-beyfortus-nirsevimab-till-nyfodda-i-sverige\/","title":{"rendered":"2025-09-10 Beyfortus (nirsevimab) till nyf\u00f6dda i Sverige"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Fr\u00e5n och med&nbsp;idag 10 september 2025&nbsp;erbjuds nyf\u00f6dda i Sverige en eng\u00e5ngsdos av den l\u00e5ngverkande monoklonala antikroppen&nbsp;<a href=\"https:\/\/www.fass.se\/LIF\/product?userType=0&amp;nplId=20220131000029\" target=\"_blank\" rel=\"noreferrer noopener\">nirsevimab (Beyfortus)<\/a>&nbsp;som skydd mot RSV. Administreringen sker p\u00e5 f\u00f6rlossning\/BB i anslutning till hemg\u00e5ng eller vid planerat \u00e5terbes\u00f6k, och insatsen avslutas n\u00e4r smittspridningen bed\u00f6ms ha avtagit under s\u00e4songen. Beslutet f\u00f6ljer NT-r\u00e5dets rekommendation inf\u00f6r s\u00e4songen 2025\/26 och kompletterar L\u00e4kemedelsverkets behandlingsrekommendationer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Folkh\u00e4lsomyndigheten har publicerat ett <a href=\"https:\/\/www.folkhalsomyndigheten.se\/contentassets\/a64445dbf42540e094f7f314220c8d92\/vilka-barn-ska-erbjudas-langverkande-monoklonal-antikropp.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">fl\u00f6desschema<\/a> f\u00f6r att underl\u00e4tta bed\u00f6mningen i v\u00e5rden:&nbsp;alla barn f\u00f6dda fr\u00e5n och med 10 september 2025&nbsp;ska erbjudas nirsevimab om&nbsp;RS-vaccination inte givits under graviditeten, om&nbsp;mindre \u00e4n 14 dagar&nbsp;f\u00f6rflutit mellan maternell vaccination och f\u00f6rlossning, eller om&nbsp;os\u00e4kerhet&nbsp;r\u00e5der kring om\/ n\u00e4r vaccination skett. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:12px\"><em><strong>EpiNytt\u00a0<\/strong><\/em>\u00e4r Reser\u00e5dets kostnadsfria omv\u00e4rldsbevakning med aktuell information om\u00a0utbrott och nyheter p\u00e5 vaccin- och resefronten. Se\u00a0<a href=\"https:\/\/resemedicin.se\/reseradet\/epinytt\/\">hela listan med nyheter i fulltext<\/a>. Dela g\u00e4rna l\u00e4nken med intresserade kolleger, vilka ocks\u00e5 sj\u00e4lva kan\u00a0<a href=\"https:\/\/resemedicin.se\/reseradet\/prenumerera-kostnadsfritt-pa-epinytt\/\">prenumerera p\u00e5 nyhetsbrevet<\/a>\u00a0utan kostnad.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fr\u00e5n och med&nbsp;idag 10 september 2025&nbsp;erbjuds nyf\u00f6dda i Sverige en eng\u00e5ngsdos av den l\u00e5ngverkande monoklonala antikroppen&nbsp;nirsevimab (Beyfortus)&nbsp;som skydd mot RSV. Administreringen sker p\u00e5 f\u00f6rlossning\/BB i anslutning till hemg\u00e5ng eller vid planerat \u00e5terbes\u00f6k, och insatsen avslutas n\u00e4r smittspridningen bed\u00f6ms ha avtagit under s\u00e4songen. Beslutet f\u00f6ljer NT-r\u00e5dets rekommendation inf\u00f6r s\u00e4songen 2025\/26 och kompletterar L\u00e4kemedelsverkets behandlingsrekommendationer. Folkh\u00e4lsomyndigheten har &hellip; <a href=\"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-09-10-beyfortus-nirsevimab-till-nyfodda-i-sverige\/\" class=\"more-link\">Forts\u00e4tt l\u00e4sa<span class=\"screen-reader-text\"> \u201d2025-09-10 Beyfortus (nirsevimab) till nyf\u00f6dda i Sverige\u201d<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"aside","meta":{"_lmt_disableupdate":"no","_lmt_disable":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-14938","post","type-post","status-publish","format-aside","hentry","category-epinytt","post_format-post-format-aside"],"modified_by":"Reser\u00e5det","jetpack_featured_media_url":"","jetpack-related-posts":[{"id":13818,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-06-05-nt-radet-beyfortus-till-riskbarn-infor-rsv-sasongen-2025-26\/","url_meta":{"origin":14938,"position":0},"title":"2025-06-05 NT-r\u00e5det: Beyfortus\u00ae till riskbarn inf\u00f6r RSV-s\u00e4songen 2025\/26","author":"Reser\u00e5det","date":"2025-06-05","format":"aside","excerpt":"Regionernas samverkansmodell f\u00f6r l\u00e4kemedel, NT-r\u00e5det, har i ett yttrande till regionerna rekommendera att Beyfortus (nirsevimab) ges som profylax mot RSV-infektion till barn f\u00f6dda fr\u00e5n och med 10 september 2025. Beyfortus ges vid f\u00f6rlossning\/BB-verksamhet antingen direkt efter f\u00f6dseln innan hemg\u00e5ng, eller vid ett ordinarie \u00e5terbes\u00f6k. NT-r\u00e5dets rekommendation till regionerna inf\u00f6r s\u00e4songen\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":14984,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-09-26-nirsevimab-77-skyddande-mot-rsv-sjukhusinlaggning-hos-spadbarn\/","url_meta":{"origin":14938,"position":1},"title":"2025-09-26 Nirsevimab 77 % skyddande mot RSV-sjukhusinl\u00e4ggning hos sp\u00e4dbarn","author":"Reser\u00e5det","date":"2025-09-26","format":"aside","excerpt":"En ny\u00a0multinationell kohortstudie\u00a0fr\u00e5n RSV-s\u00e4songen\u00a02024\u201325\u00a0visar att\u00a0nirsevimab (Beyfortus)\u00a0var\u00a077 % effektivtmot\u00a0RSV-relaterad sjukhusinl\u00e4ggning\u00a0hos sp\u00e4dbarn. Studien omfattade\u00a0409 723 sp\u00e4dbarn\u00a0i\u00a0USA, Kanada, Libanon och Saudiarabien, med data ur\u00a0Epic Cosmos\u00a0(\u22481 700 sjukhus, 40 000 mottagningar). Totalt registrerades\u00a03 385 RSV-inl\u00e4ggningar, varav\u00a0850\u00a0bland nirsevimab-exponerade och\u00a02 535\u00a0bland icke-exponerade. \u00c4ven\u00a0IVA-inl\u00e4ggningar\u00a0(324\u00a0vs\u00a0765) och\u00a0intubationer\u00a0(49\u00a0vs\u00a090) var f\u00e4rre i den behandlade gruppen. F\u00f6rfattarna konkluderar att nirsevimab fortsatt minskar\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":15925,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2026-02-02-rsv-profylax-nt-radets-rekommendation-om-beyfortus-kvarstar-aven-sasongen-2026-2027\/","url_meta":{"origin":14938,"position":2},"title":"2026-02-02 RSV-profylax: NT-r\u00e5dets rekommendation om Beyfortus\u00ae kvarst\u00e5r \u00e4ven s\u00e4songen 2026\/2027","author":"Reser\u00e5det","date":"2026-02-02","format":"aside","excerpt":"NT-r\u00e5dets nationella rekommendation f\u00f6r profylax mot RSV med den monoklonala antikroppen nirsevimab (Beyfortus\u00ae) f\u00f6r s\u00e4songen 2025\/2026 kommer att forts\u00e4tta g\u00e4lla \u00e4ven under RSV-s\u00e4songen 2026\/2027. Avtalet med l\u00e4kemedelsf\u00f6retaget har f\u00f6rl\u00e4ngts i syfte att s\u00e4kerst\u00e4lla fortsatt tillg\u00e5ng till l\u00e4kemedlet. Rekommendationen inneb\u00e4r att Beyfortus\u00ae \u00e4ven forts\u00e4ttningsvis ska anv\u00e4ndas f\u00f6r prevention av RSV-infektion hos\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":15088,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-10-20-vaccination-mot-sasongsinfluensa-och-covid%e2%80%9119-hosten-2025\/","url_meta":{"origin":14938,"position":3},"title":"2025-10-20 Vaccination mot s\u00e4songsinfluensa och covid\u201119 h\u00f6sten 2025","author":"Reser\u00e5det","date":"2025-10-20","format":"aside","excerpt":"H\u00f6stens vaccinationsinsatserna i Sverige mot s\u00e4songsinfluensa och covid-19 har inletts. Influensavaccin erbjuds i samtliga regioner och kampanjen start den\u00a014 oktober\u00a0f\u00f6r grupper som \u00e4ven rekommenderas covid-19-vaccin, medan grupper som endast omfattas av influensavaccin erbjuds vaccination fr\u00e5n\u00a04 november. F\u00f6r covid-19 har rekommendationerna \u00e4ndrats inf\u00f6r h\u00f6sten 2025. Myndigheten rekommenderar fr\u00e5n och med den\u00a01\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":15027,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-01-05-rsv-vaccin-bekraftat-sakert-och-effektivt-enligt-ny-cochrane-oversikt\/","url_meta":{"origin":14938,"position":4},"title":"2025-10-05 RSV-vaccin \u2013 bekr\u00e4ftat s\u00e4kert och effektivt enligt ny Cochrane-\u00f6versikt","author":"Reser\u00e5det","date":"2025-10-05","format":"aside","excerpt":"En ny systematisk \u00f6versikt fr\u00e5n\u00a0Cochrane Collaboration, publicerad i september 2025, bekr\u00e4ftar att\u00a0RSV-vacciner \u00e4r b\u00e5de effektiva och s\u00e4kra\u00a0f\u00f6r vuxna och \u00e4ldre personer. Analysen omfattade\u00a0\u00f6ver 100 000 studiedeltagare\u00a0i flera randomiserade fas 3-studier. Resultaten visar att vaccination\u00a0minskar risken f\u00f6r RSV-orsakad luftv\u00e4gsinfektion med cirka 80 %\u00a0och\u00a0sv\u00e5r sjukdom med upp till 90 %\u00a0under den f\u00f6rsta\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":16033,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2026-02-19-influensavaccinets-effekt-under-dominans-av-driftad-ah3n2-subklad-k\/","url_meta":{"origin":14938,"position":5},"title":"2026-02-19 Influensavaccinets effekt under dominans av driftad A(H3N2) subklad K","author":"Reser\u00e5det","date":"2026-02-19","format":"aside","excerpt":"En artikel i Eurosurveillance med titeln\u00a0\u201cInfluenza vaccine effectiveness from nine studies during drifted A(H3N2) subclade K predominance, Europe, September 2025 to January 2026\u201d\u00a0sammanfattar tidiga europeiska data om influensavaccinets skyddseffekt under den p\u00e5g\u00e5ende s\u00e4songen. Under perioden september 2025\u2013januari 2026 dominerade en antigeniskt driftad influensa A(H3N2)-subklad (subklad K) i Europa. Trots detta\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts\/14938","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/comments?post=14938"}],"version-history":[{"count":3,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts\/14938\/revisions"}],"predecessor-version":[{"id":14961,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts\/14938\/revisions\/14961"}],"wp:attachment":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/media?parent=14938"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/categories?post=14938"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/tags?post=14938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}